Stockscreener 앱 받기
11.30
0.00%
0.00
시간 외 거래:
11.48
0.18
+1.59%
전일 마감가:
$11.30
열려 있는:
$11.45
하루 거래량:
43,529
Relative Volume:
0.40
시가총액:
$494.68M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.67%
1개월 성능:
-0.18%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$11.22
$11.63
1주일 범위
$10.54
$13.04
52주 변동 폭
$10.08
$16.09
Maze Therapeutics Inc Stock (MAZE) Company Profile
MAZE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
11.30 | 494.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Quiet Period To End on March 12th - Defense World
Leerink Partners Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.6%Still a Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Guggenheim Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Upgraded at TD Cowen - Defense World
FY2024 Earnings Forecast for MAZE Issued By Leerink Partnrs - Defense World
FY2024 Earnings Estimate for MAZE Issued By Leerink Partnrs - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at JPMorgan Chase & Co. - Defense World
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Guggenheim - Defense World
Maze Therapeutics (NASDAQ:MAZE) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Maze Therapeutics initiated with a Buy at TD Cowen - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Leerink Partners - Defense World
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829 - TipRanks
Cowen initiates Maze Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Maze Therapeutics receives positive ratings following recent IPO - Investing.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Guggenheim sets $19 target on Maze Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target -February 25, 2025 at 06:43 am EST - Marketscreener.com
JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target -February 25, 2025 at 06:32 am EST - Marketscreener.com
Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics - TipRanks
Maze Therapeutics initiated with an Outperform at Leerink - TipRanks
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market - TipRanks
JPMorgan sets Maze Therapeutics stock to Overweight with $30 target By Investing.com - Investing.com Canada
This New Drug Mimics The Health Effects of Living at High Altitude - ScienceAlert
Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month LowShould You Sell? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month Low – Here’s Why - Armenian Reporter
Maze Therapeutics (NASDAQ:MAZE) Shares Down 3.9%Here's Why - MarketBeat
Maze Therapeutics begins Phase 2 trial for kidney disease drug - MSN
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Maze Therapeutics doses first subject in Phase II AKD treatment trial - Yahoo Finance
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Maze Therapeutics’ $140 Million Upsized Initial Public Offering - Global Legal Chronicle
Cyclo Therapeutics reports promising NPC1 treatment findings - MSN
Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Investing.com Australia
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Groundbreaking Kidney Disease Trial: Maze's APOL1 Inhibitor Targets 1M+ Patient Market - StockTitan
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Metsera, Maze land on NASDAQ as IPO queue grows - BioCentury
Biotech firm Maze Therapeutics raises $140 million in US IPO - MSN
Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Maze Therapeutics IPO opens trading modestly higher - MSN
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut - MSN
Maze Therapeutics IPO opens trading modestly higher By Investing.com - Investing.com Canada
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Maze Therapeutics Opens At $16.12, IPO Priced At $16 By Investing.com - Investing.com Canada
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
FiDi-based obesity drug maker sees $1.9B IPO - Crain's New York Business
Maze Therapeutics Inc (MAZE) 재무 분석
Maze Therapeutics Inc (MAZE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):